Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 540, rue d'Avaugour, Office 1800 BOUCHERVILLE QC J4B 0G6 |
Tel: | N/A |
Website: | N/A |
IR: | N/A |
Key People | ||
Marcel R. Tremblay Chairman of the Board | Alain Larochelle President, Chief Executive Officer, Director | Luc Mainville Chief Financial Officer, Senior Vice President | Pierre-Hubert Seguin Secretary, Director |
Business Overview |
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company. The Company is specializing in the development, manufacturing and distribution of natural health products and dietary supplements in solid dosage forms, as well as sterile ophthalmic pharmaceutical products. The Company's subsidiaries include Steri-Med Pharma Inc., LSL Laboratory Inc. and Groupe Immobilier LSL inc. |
Financial Overview |
For the fiscal year ended 31 December 2023, LSL Pharma Group Inc revenues totaled C$10M. Net loss totaled to C$8.5M. Results are not comparable due to year end change. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $70.36M as of Dec 31, 2023 |
Annual revenue (TTM): | $10.03M as of Dec 31, 2023 |
EBITDA (TTM): | -$0.58M as of Dec 31, 2023 |
Net annual income (TTM): | -$8.47M as of Dec 31, 2023 |
Free cash flow (TTM): | -$8.09M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $16.26M as of Dec 31, 2023 |
Shares outstanding: | 108,240,370 as of Apr 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |